Latest Conference Articles

May 29th 2015, 2:14pm

ASCO Annual Meeting

In a multisite study offering the largest experience to date of how immunotherapy can be deployed in patients with head and neck cancer, the anti-PD-1 antibody pembrolizumab produced broad and durable responses in patients with advanced disease.

May 29th 2015, 2:01pm

ASCO Annual Meeting

Treatment with the PD-1 inhibitor pembrolizumab demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair.

May 28th 2015, 3:09pm

ASCO Annual Meeting

Howard Burris, III, MD, chief medical officer and executive director of Drug Development at the Sarah Cannon Research Institute discusses the importance of the ASCO annual meeting, taking place May 29 - June 2.

May 27th 2015, 9:46am

ASCO Annual Meeting

Findings from large, late-stage clinical trials in melanoma, non–small cell lung cancer, and several hematologic malignances are expected to rank among the most clinically significant research findings presented at the 2015 American Society of Clinical Oncology Annual Meeting.

May 20th 2015, 2:13pm

AUA Annual Meeting

Prior treatment with abiraterone acetate or enzalutamide did not alter the survival benefit seen with radium-223 in men with advanced castration-resistant prostate cancer.

May 20th 2015, 12:58pm

AUA Annual Meeting

Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, managing partner, Atlantic Urology Clinics, discusses the results of the TERRAIN trial.

May 20th 2015, 12:37pm

AUA Annual Meeting

Prostate cancer patients with different baseline cardiovascular risk had similar reductions in cardiovascular event rates when treated with the LHRH antagonist degarelix versus an LHRH agonist.

May 19th 2015, 10:21am

AUA Annual Meeting

Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco, discusses the efficacy of using an antagonist with hormone therapy in prostate cancer.

May 19th 2015, 9:30am

AUA Annual Meeting

A fourth of patients with advanced urothelial cancer had objective responses to treatment with the immune checkpoint inhibitor pembrolizumab.

May 18th 2015, 2:05pm

AUA Annual Meeting

The combination of multiparametric MRI with a fusion-guided biopsy (MRI plus ultrasound) was more effective at detecting aggressive prostate cancer compared with either procedure alone.

May 18th 2015, 12:16pm

AUA Annual Meeting

A cell-surface proteoglycan found on prostate cancer cells but not normal prostate tissue demonstrated good specificity as a blood test for prostate cancer.

May 18th 2015, 10:29am

AUA Annual Meeting

Sexual function scores were better for patients who had a robotic compared with open surgery for prostate cancer; however, comparative results for urinary function were not conclusive.

May 18th 2015, 8:05am

AUA Annual Meeting

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses a recent study that demonstrated the impact of obesity on active surveillance.

May 18th 2015, 6:54am

AUA Annual Meeting

Brock O'Neil, MD, physician, instructor in urologic surgery, Vanderbilt University, discusses a study that demonstrated evidence of superior quality of life after robotic assisted radical prostatectomy.

May 17th 2015, 2:40pm

AUA Annual Meeting

Since the USPSTF guideline on PSA screening the overall rate of PSA testing decreased by 50% among primary care physicians at Oregon Health & Science University.

May 17th 2015, 2:28pm

AUA Annual Meeting

A urine assay that targets expression of exosomal messenger RNA demonstrated high negative predictive value for high-grade prostate cancer in a study that validates the emerging test as a tool to help determine whether patients need initial biopsies.

May 17th 2015, 11:16am

AUA Annual Meeting

Enzalutamide significantly improved progression-free survival, PSA kinetics, and quality of life compared with bicalutamide in men with castration-resistant prostate cancer.

May 17th 2015, 7:58am

AUA Annual Meeting

Kyle A. Richards, MD, assistant professor, University of Wisconsin, discusses the association between urinary tract infections (UTI) and worse bladder cancer outcomes in the Medicare population.

May 17th 2015, 5:03am

AUA Annual Meeting

Michael Brawer, MD, vice president of Medical Affairs, Myriad Genetic Laboratories, discusses the clinical utility of the cell cycle progression (CCP) test in personalizing prostate cancer treatment.

May 16th 2015, 2:37pm

AUA Annual Meeting

As the AS strategy gains a foothold among urologists both here in the US and around the world, a study presented at the 110th Annual Scientific Meeting of the American Urological Association suggests that among men in the US, very few are following the stringent protocol for AS that is recommended by major academic institutions.